Detalhe da pesquisa
1.
Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
EBioMedicine
; 99: 104922, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38128414